Strides gets US health regulator nod for anti-bacterial capsules
In an interview to NDTV Profit, he said that that IGL is yet to work on the liabilities of the order. “There won’t be immediate cuts in CNG, PNG prices,” he clarified.
Drug firm Strides Arcolab on Wednesday said it has received approval from the US health regulator to market its generic vancomycin hydrochloride capsules used for treating bacterial infections in the American market.
The company plans to immediately launch the product through US-headquartered firm Alvogen on a profit sharing basis, the company said in a statement.
The firm has received approval from US Food and Drug Administration (USFDA) for vancomycin hydrochloride capsules USP in the strengths of 125 mg and 250 mg, it added.
Commenting on the development, Strides Group chief executive Arun Kumar said, "Oral vancomycin development is one among the many value generics programmes being undertaken at the Strides group with a special focus to develop niche and difficult-to-manufacture products".
According to IMS health data, vancomycin capsules had total US sales of $332 million for the twelve months ending February 12, Strides said.
The use of vancomycin capsules in prevention and treatment of infections caused by ‘gram-positive bacteria’ is considered only after treatment with other antibiotics has failed, it added.